{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:58:47Z","timestamp":1774605527389,"version":"3.50.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>With poor treatment outcomes and prognosis, bladder cancer remains a focus for clinical research in the precision oncology era. However, the potential of disulfidptosis, a novel cell death mechanism, and its related long non-coding RNAs to support selective cancer cell killing in this disease is still unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified key disulfidptosis-related lncRNAs in bladder cancer, constructed a prognostic risk model with potential therapeutic targets, and confirmed the findings through quantitative PCR analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified five crucial lncRNAs (<jats:italic>AC005840.4<\/jats:italic>, <jats:italic>AC010331.1, AL021707.6<\/jats:italic>, <jats:italic>MIR4435-2HG<\/jats:italic> and <jats:italic>ARHGAP5-AS1<\/jats:italic>) and integrated them into a predictive model centered on disulfidptosis-associated lncRNAs. Reliability and validity tests demonstrated that the lncRNA prediction index associated with disulfidptosis effectively discerns patients\u2019 prognosis outcomes. Additionally, high-risk patients exhibited elevated expression levels of genes involved in the PI3K-Akt signaling pathway, extracellular matrix organization, and immune escape mechanisms, which are associated with poor prognosis. Notably, high-risk patients demonstrated higher sensitivity to <jats:italic>Sorafenib<\/jats:italic>, <jats:italic>Oxaliplatin<\/jats:italic> and <jats:italic>MK-2206<\/jats:italic>, underscoring the promise of these lncRNAs as precise therapeutic targets in bladder cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>By revealing the predictive importance of disulfidptosis-associated lncRNAs in bladder cancer, our research offers new perspectives and pinpoints potential therapeutic targets in clinical environments.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1512203","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T06:23:50Z","timestamp":1733120630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic model based on disulfidptosis-related lncRNAs for predicting survival and therapeutic response in bladder cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Lirui","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hankai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kairan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guofang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medsci8010015","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: A global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/551S33a","article-title":"Bladder cancer","volume":"551","author":"Grayson","year":"2017","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"B7","article-title":"Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients","volume-title":"Urologic Oncology: Seminars and Original Investigations","author":"Mertens","year":""},{"key":"B8","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.3390\/ijms21093360","article-title":"Diagnostic and prognostic potential of biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in bladder cancers","volume":"21","author":"Matuszczak","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1158\/2159-8290.CD-11-0209","article-title":"The emergence of lncRNAs in cancer biology","volume":"1","author":"Prensner","year":"2011","journal-title":"Cancer Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.03.010","article-title":"Long noncoding RNAs in cancer pathways","volume":"29","author":"Schmitt","year":"2016","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12935-023-03065-8","article-title":"Disulfidptosis-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in colon adenocarcinoma","volume":"23","author":"Xue","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e25573","DOI":"10.1016\/j.heliyon.2024.e25573","article-title":"Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer","volume":"10","author":"Pan","year":"2024","journal-title":"Heliyon"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3981","article-title":"The emerging role of lncRNAs in cancer","volume":"21","author":"Huarte","year":"2015","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-023-01091-2","article-title":"Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis","volume":"25","author":"Liu","year":"2023","journal-title":"Nat Cell Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"104438","DOI":"10.1016\/j.critrevonc.2024.104438","article-title":"Metabolic vulnerabilities in cancer: A new therapeutic strategy","volume":"201","author":"El-Tanani","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2023.07.009","article-title":"Disulfidptosis: disulfide stress\u2013induced cell death","volume":"34","author":"Liu","year":"2024","journal-title":"Trends Cell Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00339-6","article-title":"Targeting cancer metabolism in the era of precision oncology","volume":"21","author":"Stine","year":"2022","journal-title":"Nat Rev Drug Discovery"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/procel\/pwae003","article-title":"Metabolic cell death in cancer: Ferroptosis, cuproptosis, disulfidptosis, and beyond","volume":"15","author":"Mao","year":"2024","journal-title":"Protein Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3390\/cancers14071681","article-title":"Dual effect of immune cells within tumor microenvironment: pro-and anti-tumor effects and their triggers","volume":"14","author":"Pe\u00f1a-Romero","year":"2022","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.21037\/tlcr.2018.08.04","article-title":"Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not","volume":"7","author":"Heeke","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41392-022-01110-y","article-title":"Regulated cell death (RCD) in cancer: key pathways and targeted therapies","volume":"7","author":"Peng","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2007.01.065","article-title":"Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects","volume":"69","author":"Silay","year":"2007","journal-title":"Med Hypotheses"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.11.050","article-title":"Co-delivery of oxaliplatin prodrug liposomes with Bacillus Calmette-Gu\u00e9rin for chemo-immunotherapy of orthotopic bladder cancer","volume":"365","author":"Ma","year":"2024","journal-title":"J Control Release"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.06.004","article-title":"Targeting the genetic alterations of the PI3K\u2013AKT\u2013mTOR pathway: Its potential use in the treatment of bladder cancers","volume":"145","author":"Hou\u00e9d\u00e9","year":"2015","journal-title":"Pharmacol Therapeutics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non\u2013muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Network Open"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-02028-1","article-title":"Synergism between the phosphatidylinositol 3-kinase p110\u03b2 isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation","volume":"21","author":"Zhao","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B27","doi-asserted-by":"publisher","first-page":"v17","DOI":"10.1093\/annonc\/mdz238.059","article-title":"Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells","volume":"30","author":"Cheng","year":"2019","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1615\/CritRevEukaryotGeneExpr.2023048536","article-title":"Prognosis prediction of disulfidptosis-related genes in bladder cancer and a comprehensive analysis of immunotherapy","volume":"33","author":"Jiang","year":"2023","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198878","article-title":"Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12894-024-01454-3","article-title":"Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature","volume":"24","author":"Tang","year":"2024","journal-title":"BMC Urol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1180404","article-title":"Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.11.009","article-title":"Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis","volume":"41","author":"Wang","year":"2014","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3214","article-title":"The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention","volume":"12","author":"Peters","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1512203\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T06:23:53Z","timestamp":1733120633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1512203\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2024.1512203"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1512203","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"article-number":"1512203"}}